Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Non Operating Income (2020 - 2025)

Cytek Biosciences' Non Operating Income history spans 6 years, with the latest figure at $258000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income fell 96.48% year-over-year to $258000.0; the TTM value through Dec 2025 reached $9.0 million, down 33.4%, while the annual FY2025 figure was $8.8 million, 40.63% down from the prior year.
  • Non Operating Income reached $258000.0 in Q4 2025 per CTKB's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $7.5 million in Q4 2023 to a low of -$946000.0 in Q1 2022.
  • Average Non Operating Income over 5 years is $1.7 million, with a median of $1.5 million recorded in 2023.
  • Peak YoY movement for Non Operating Income: tumbled 350.14% in 2021, then surged 6184.75% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$873000.0 in 2021, then skyrocketed by 327.26% to $2.0 million in 2022, then surged by 279.84% to $7.5 million in 2023, then decreased by 2.64% to $7.3 million in 2024, then plummeted by 96.48% to $258000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Non Operating Income are $258000.0 (Q4 2025), $1.3 million (Q3 2025), and $3.7 million (Q2 2025).